Canine Tumor Classification and Treatment Strategies

Canine neoplasia encompasses a diverse array of tumour types, ranging from mast cell tumours and soft tissue sarcomas to glandular adenocarcinomas. Accurate classification draws upon histological grading, molecular profiling and staging to predict behaviour and guide therapy. Traditional approaches such as wide surgical excision and radiotherapy remain cornerstones for local control, while systemic strategies now include receptor tyrosine kinase inhibitors, intratumoural agents and immunotherapies. Recent advances in genomic and transcriptomic analyses have refined our understanding of molecular drivers—such as TP53 and KMT family mutations, PDGFB fusions and c-KIT aberrations—enabling more precise risk stratification and identification of actionable targets. Multimodal regimens tailored to tumour subtype, grade and metastatic risk are yielding improved outcomes, with emerging techniques offering minimally invasive options and biomarker-driven treatment selection. Global collaboration and standardised diagnostic criteria continue to underpin progress, translating bench discoveries into clinical benefit for canine patients and offering comparative insights for human oncology.

Research from Nature Portfolio

An integrative genomic and transcriptomic study of spontaneous canine soft tissue sarcomas characterised fibrosarcoma, pleomorphic sarcoma and peripheral nerve sheath tumours through whole-exome sequencing, RNA-seq and immunohistochemistry. This work identified recurrent mutations in TP53 and chromatin-modifying genes (notably KMT2D) in over one-third of cases, and uncovered PDGFB fusion transcripts predicting sensitivity to PDGFR inhibitors. Transcriptomic clustering delineated four molecular subgroups with distinct extracellular matrix, homeobox transcription factor or immune-infiltration signatures, providing a framework for refined diagnosis, comparative oncology studies and prioritisation of targeted therapy trials in pet dogs.

Canine Tumor Classification and Treatment Strategies publication trend

The graph below shows the total number of articles in canine tumor classification and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Histologic grade: A scale assessing tumour cell differentiation and mitotic activity under the microscope to predict biological behaviour.

Ki67 proliferation index: The proportion of tumour cells expressing the nuclear Ki67 protein, used as a marker of cell division and aggressiveness.

Fusion transcript: An aberrant RNA molecule resulting from the joining of two separate genes, often creating an oncogenic driver amenable to targeted inhibition.

Intratumoural injection: Delivery of therapeutic agents directly into the tumour mass to achieve high local concentration and minimise systemic exposure.

Multi-omics: An integrative approach combining genomic, transcriptomic and other molecular data to characterise tumour heterogeneity and identify therapeutic targets.

References

1. Oxidative Status and Lipid Metabolism Analytes in Dogs with Mast Cell Tumors: A Preliminary Study. Antioxidants (2024).
2. Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Frontiers in Veterinary Science (2021).
3. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Frontiers in Veterinary Science (2019).
4. Integrated analysis of canine soft tissue sarcomas identifies recurrent mutations in TP53, KMT genes and PDGFB fusions. Scientific Reports (2023).